Related Experiment Video

Updated: May 12, 2026

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry
10:16

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry

Published on: January 6, 2017

TLN1 interacts with NGFR and suppresses the development of castration-resistant prostate cancer by upregulating NGFR

Sixin Li1,2, Anjie Chen1,2, Chen Guo1,2

  • 1Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.

Frontiers in Immunology
|May 11, 2026
PubMed
Abstract

Insights

Talin-1 (TLN1) promotes castration-resistant prostate cancer (CRPC) progression by interacting with nerve growth factor receptor (NGFR). Targeting the TLN1/NGFR axis offers a new therapeutic strategy for CRPC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Prostate cancer (PCa) is a prevalent malignancy in males.
  • Castration-resistant prostate cancer (CRPC) signifies an advanced stage with limited therapeutic options and poor prognosis.
  • The role of Talin-1 (TLN1) in CRPC progression is not well-understood.

Purpose of the Study:

  • To investigate the role and mechanism of Talin-1 (TLN1) in castration-resistant prostate cancer (CRPC).
  • To identify potential therapeutic targets for CRPC based on TLN1's function.

Main Methods:

  • Serum peptide analysis using mass spectrometry (MS).
  • Validation of TLN1 expression in clinical samples via immunohistochemistry, qPCR, and Western blot.
  • Functional assays and in vivo xenograft models to assess TLN1 knockdown effects.
  • Transcriptome sequencing, molecular docking, and co-immunoprecipitation (Co-IP) to elucidate mechanisms and interactions.
  • Analysis of signaling pathways (PI3K-AKT, MAPK, NF-κB) and rescue experiments involving nerve growth factor receptor (NGFR).

Main Results:

  • TLN1 expression is significantly upregulated in CRPC patient serum and tissues.
  • TLN1 knockdown inhibits CRPC cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and promotes apoptosis, suppressing tumor growth in vivo.
  • TLN1 interacts directly with NGFR, and TLN1 knockdown upregulates NGFR, influencing CRPC progression via MAPK and PI3K-AKT pathways. NGFR knockdown reverses TLN1 silencing effects.

Conclusions:

  • Talin-1 (TLN1) promotes CRPC progression by interacting with and regulating the tumor suppressor nerve growth factor receptor (NGFR).
  • The TLN1/NGFR axis is identified as a novel potential therapeutic target for CRPC.
Keywords:
NGFRTLN1castration-resistant prostate cancerprostate cancertherapeutic target

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...